| 000 | 01666 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250513235814.0 | ||
| 264 | 0 | _c20010920 | |
| 008 | 200109s 0 0 eng d | ||
| 022 | _a0960-894X | ||
| 024 | 7 |
_a10.1016/s0960-894x(01)00120-2 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBeaton, H | |
| 245 | 0 | 0 |
_aThienopyridines: nitric oxide synthase inhibitors with potent in vivo activity. _h[electronic resource] |
| 260 |
_bBioorganic & medicinal chemistry letters _cApr 2001 |
||
| 300 |
_a1027-30 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aBlood Pressure _xdrug effects |
| 650 | 0 | 4 | _aCells, Cultured |
| 650 | 0 | 4 |
_aCerebellum _xcytology |
| 650 | 0 | 4 |
_aCyclopropanes _xchemical synthesis |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xchemical synthesis |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIn Vitro Techniques |
| 650 | 0 | 4 | _aInhibitory Concentration 50 |
| 650 | 0 | 4 |
_aLipopolysaccharides _xpharmacology |
| 650 | 0 | 4 | _aModels, Animal |
| 650 | 0 | 4 |
_aNitric Oxide Synthase _xantagonists & inhibitors |
| 650 | 0 | 4 | _aNitric Oxide Synthase Type I |
| 650 | 0 | 4 | _aNitric Oxide Synthase Type II |
| 650 | 0 | 4 |
_aNitrites _xagonists |
| 650 | 0 | 4 |
_aPyridines _xchemical synthesis |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 |
_aomega-N-Methylarginine _xpharmacology |
| 700 | 1 | _aBoughton-Smith, N | |
| 700 | 1 | _aHamley, P | |
| 700 | 1 | _aGhelani, A | |
| 700 | 1 | _aNicholls, D J | |
| 700 | 1 | _aTinker, A C | |
| 700 | 1 | _aWallace, A V | |
| 773 | 0 |
_tBioorganic & medicinal chemistry letters _gvol. 11 _gno. 8 _gp. 1027-30 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0960-894x(01)00120-2 _zAvailable from publisher's website |
| 999 |
_c11261495 _d11261495 |
||